B. Riley Has Negative Estimate for Harrow Q2 Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at B. Riley cut their Q2 2025 earnings per share (EPS) estimates for Harrow in a research note issued on Wednesday, May 28th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.17. B. Riley has a "Buy" rating and a $65.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.64 EPS, FY2025 earnings at $0.56 EPS and FY2026 earnings at $3.10 EPS.

Separately, HC Wainwright raised their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th.

Harrow Trading Up 3.8%

Shares of NASDAQ:HROW traded up $1.04 on Friday, hitting $28.24. 642,462 shares of the company's stock were exchanged, compared to its average volume of 495,794. Harrow has a 12 month low of $16.71 and a 12 month high of $59.23. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -30.04 and a beta of 0.41. The business's 50 day simple moving average is $25.18 and its two-hundred day simple moving average is $30.39. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million.

Hedge Funds Weigh In On Harrow

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after purchasing an additional 39,506 shares during the last quarter. Sonora Investment Management Group LLC purchased a new position in Harrow in the fourth quarter valued at about $518,000. Northern Trust Corp grew its stake in Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after purchasing an additional 22,266 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Harrow by 8.4% in the fourth quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock valued at $2,900,000 after purchasing an additional 6,690 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.